cityslickers, Bear, others, etc ... Do you think RVX will/should pursue approvals to market apabetalone's benefits in other domains outside the FDA sphere of influence (China, Japan, Europe, Israel, India, etc), concurrently with the FDA efforts? ... duh?

For example:  diabetics with/without known cardiac issues and eGFR<60, and a strong safety profile?

Can't think of a more practical and better way to further study, if appropriate?

Or is this a breach of etiquette and appropriate process, at this point?

Maybe among the things Don could address tomorrow on the "business" end of things, along with other hints or direct messaging about future opportunties, plans, partnering, and the path ahead ..... ?